Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 2000/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vétoquinol sa-nv - amoxicillin trihydrate - eq. amoxicillin 50 mg; clavulanic acid 12,5 mg - tablet - 62,5 mg - clavulanic acid 12.5 mg; amoxicillin trihydrate - amoxicillin - dog; cat

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - amoxicillin trihydrate - eq. amoxicillin 250 mg/5 ml; clavulanic acid 12,5 mg/ml - powder for oral suspension - 250 mg/5 ml - 62,5 mg/5 ml - clavulanic acid 12.5 mg/ml; amoxicillin trihydrate - amoxicillin and enzyme inhibitor

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

livisto int'l s.l. - potassium clavulanate 14,89 mg - eq. clavulanic acid 12,5 mg; amoxicillin trihydrate 57,4 mg - eq. amoxicillin 50 mg - tablet - 50 mg - 12,5 mg - amoxicillin trihydrate 57.4 mg; potassium clavulanate 14.89 mg - amoxicillin and enzyme inhibitor - dog; cat

Malta - Ingliż - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - amoxicillin, clavulanic acid - film-coated tablet - amoxicillin 250 mg clavulanic acid 125 mg - antibacterials for systemic use

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; sodium lauryl sulfate; cetyl alcohol - short-term treatment of bacterial infections at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms: skin and skin structure infections. urinary tract infections (complicated and uncomplicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablet preparations. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections cause by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxycillin/clavulanic acid tablet preparations should not require the addition of another antibiotic due to the amoxycillin content of these products.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; sodium lauryl sulfate; cetyl alcohol - short-term treatment of bacterial infections at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms: skin and skin structure infections. urinary tract infections (complicated and uncomplicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablet preparations. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections cause by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxycillin/clavulanic acid tablet preparations should not require the addition of another antibiotic due to the amoxycillin content of these products.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

h.j. harkins company, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 500 mg - amoxicillin and clavulanate potassium tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. caused by β-lactamase-producing strains of e. coli , klebsiella spp., and enterobacter spp. while amoxicillin and clavulanate potassium tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium tablets due to their amoxicillin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate po

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - amoxicillin trihydrate 57,4 mg/ml - eq. amoxicillin 50 mg/ml; potassium clavulanate 14,89 mg/ml - eq. clavulanic acid 12,5 mg/ml - powder for oral suspension - 250 mg - clavulanic acid 14.9 mg/ml; amoxicillin trihydrate 57.4 mg/ml - amoxicillin and enzyme inhibitor

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - amoxicillin; clavulanic acid - tablet - 50, 12.5 mg/tablet - amoxicillin and enzyme inhibitor